GLP-1's Expanding Horizons: Beyond Weight Loss
GLP-1 receptor agonists offer significant benefits beyond weight loss, including reducing major cardiovascular events, slowing chronic kidney disease progression, and improving fatty liver disease markers.
The top 3
- Top 3 Cardiovascular Benefits Identified: GLP-1 RAs consistently reduce major adverse cardiovascular events (MACE) such as myocardial infarction, stroke, and cardiovascular death, even in individuals without diabetes but with obesity and established cardiovascular disease.
- Emerging Applications: Kidney & Liver: GLP-1 RAs have demonstrated renoprotective actions, slowing chronic kidney disease progression, and positively impact liver health by improving steatosis and liver inflammation in non-alcoholic fatty liver disease (NAFLD).
- Potential in Neurological Disorders Research: Preclinical and some clinical studies suggest GLP-1 RAs have neuroprotective effects, showing potential in treating neurodegenerative diseases like Parkinson's and Alzheimer's, and conditions like idiopathic intracranial hypertension.
Sources
Open the full topic